Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Thus, these features should be considered in the design of future clinical studies aimed at testing ASNase efficacy in AML patients.
|
31044436 |
2019 |
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
L-asparaginase is an indispensable component of the chemotherapeutic treatment of acute lymphoblast leukaemia (ALL) and acute myeloid leukaemia (AML).
|
29159986 |
2018 |
Leukemia, Myelocytic, Acute
|
0.180 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.
|
28224619 |
2017 |
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Importantly, both ASNS gene and protein expression were significantly lower in -7 AML cell lines, suggesting that haploinsufficiency of <i>ASNS</i> might induce sensitivity to L-Asp in AMLs.
|
29299118 |
2017 |
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
|
26154683 |
2015 |
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.
|
23016580 |
2013 |
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
The knockdown of the SLC1A5 high-affinity transporter for glutamine induces apoptosis and inhibits tumor formation in a mouse AML xenotransplantation model. l-asparaginase (l-ase) is an anticancer agent also harboring glutaminase activity.
|
24014241 |
2013 |
Leukemia, Myelocytic, Acute
|
0.180 |
GeneticVariation
|
disease |
BEFREE |
Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
|
20804919 |
2010 |